Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02644785
Other study ID # 2014/10
Secondary ID
Status Completed
Phase N/A
First received December 24, 2015
Last updated March 21, 2017
Start date January 2016
Est. completion date February 2016

Study information

Verified date February 2016
Source Mustafa Kemal University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators aim to assess tryptase test efficacy for measuring the allergic response to protamine during cardiac bypass surgery. Additionally, the investigators aim to establish a differential diagnosis on the basis of potential allergens or clinical causes.


Description:

Venous blood samples from cardiac surgery cases will be obtained for tryptase measurement upon admission to the operating room (OR) and immediately prior to and 30 min after protamine infusion initiation. A rapid effect-response-based clinical assessment will be made using clinical and laboratory monitoring data for diagnosis and treatment decisions during protamine infusion, which may complicate the recovery from surgery.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date February 2016
Est. primary completion date February 2016
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria:

- Cardiac by-pass cases

Exclusion Criteria:

- Insulin dependent diabetes

- Atopy

- Drug allergy history

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
protamine
Protamine infusion exposures

Locations

Country Name City State
Turkey Mustafa Kemal University Hospital Hatay

Sponsors (1)

Lead Sponsor Collaborator
Mustafa Kemal University

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

Krishna MT, York M, Chin T, Gnanakumaran G, Heslegrave J, Derbridge C, Huissoon A, Diwakar L, Eren E, Crossman RJ, Khan N, Williams AP. Multi-centre retrospective analysis of anaphylaxis during general anaesthesia in the United Kingdom: aetiology and diag — View Citation

Malinovsky JM, Decagny S, Wessel F, Guilloux L, Mertes PM. Systematic follow-up increases incidence of anaphylaxis during adverse reactions in anesthetized patients. Acta Anaesthesiol Scand. 2008 Feb;52(2):175-81. — View Citation

Mertes PM, Laxenaire MC, Alla F; Groupe d'Etudes des Réactions Anaphylactoïdes Peranesthésiques.. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology. 2003 Sep;99(3):536-45. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Patients number with high tryptase level (> 25 µg/L ). Tryptase will be measured using the ImmunoCAP Tryptase kit (Phadia, Uppsala, Sweden), and the cutoff level for elevated tryptase is >11.5 µg/L. A 25 µg/L cutoff value has been found to be highly suggestive of an Immunoglobulin E (IgE) -mediated reaction. 30 min
Secondary Patients number with allergic reaction involving of 1 or more organ/systems (skin, respiratory, or cardiovascular system) following the study drug infusion. In this study, mainly the cardiovascular and skin symptoms will be focused on. These outcomes will be determined following the Council for International Organizations of Medical Sciences (CIOMS 1999 and ) definitions for anaphylactic reactions. Additionally, (World Health Organization - Uppsala Monitoring Centre) WHO-UMC system will be used for assesment of causality categories for adverse drug reactions. 30 min
See also
  Status Clinical Trial Phase
Completed NCT03583567 - Effect of Anti-histamine in Prevention Systolic Hypotension After Protamine Phase 4
Not yet recruiting NCT06254404 - Impact of Protamine Dose Reduction on Platelet Aggregation After Extracorporeal Circulation for Minimally Invasive Aortic Valve Replacement Surgery N/A